The DEA's April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, providing immediate tax relief under Section 280E for qualifying entities while leaving recreational and unlicensed marijuana in Schedule I. An expedited administrative hearing on broader rescheduling to Schedule III began June 29 and concluded by July 15, 2026, with all parties submitting closing briefs in August; DEA's post-hearing filing stated cannabis can no longer remain in Schedule I based on HHS scientific review. The administrative law judge's recommendation remains pending amid a D.C. Circuit challenge to the partial order and ongoing compliance with international treaty obligations. These procedural milestones and the administration's directive for expeditious action shape trader views on timelines for any further DEA rulemaking.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$802,588 Wol.
Dec 31, 2026
September 30
2%
December 31
26%
$802,588 Wol.
September 30
$262 Wol.
2%
December 31
$192,755 Wol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA's April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, providing immediate tax relief under Section 280E for qualifying entities while leaving recreational and unlicensed marijuana in Schedule I. An expedited administrative hearing on broader rescheduling to Schedule III began June 29 and concluded by July 15, 2026, with all parties submitting closing briefs in August; DEA's post-hearing filing stated cannabis can no longer remain in Schedule I based on HHS scientific review. The administrative law judge's recommendation remains pending amid a D.C. Circuit challenge to the partial order and ongoing compliance with international treaty obligations. These procedural milestones and the administration's directive for expeditious action shape trader views on timelines for any further DEA rulemaking.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Feb 7, 2026, 5:04 PM ET
Wolumen
$802,588Data zakończenia
Jan 1, 2027Rynek otwarty
Feb 7, 2026, 5:04 PM ETRozstrzygający
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA's April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, providing immediate tax relief under Section 280E for qualifying entities while leaving recreational and unlicensed marijuana in Schedule I. An expedited administrative hearing on broader rescheduling to Schedule III began June 29 and concluded by July 15, 2026, with all parties submitting closing briefs in August; DEA's post-hearing filing stated cannabis can no longer remain in Schedule I based on HHS scientific review. The administrative law judge's recommendation remains pending amid a D.C. Circuit challenge to the partial order and ongoing compliance with international treaty obligations. These procedural milestones and the administration's directive for expeditious action shape trader views on timelines for any further DEA rulemaking.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Wolumen
$802,588Data zakończenia
Jan 1, 2027Rynek otwarty
Feb 7, 2026, 5:04 PM ETRozstrzygający
0x65070BE91...The DEA's April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, providing immediate tax relief under Section 280E for qualifying entities while leaving recreational and unlicensed marijuana in Schedule I. An expedited administrative hearing on broader rescheduling to Schedule III began June 29 and concluded by July 15, 2026, with all parties submitting closing briefs in August; DEA's post-hearing filing stated cannabis can no longer remain in Schedule I based on HHS scientific review. The administrative law judge's recommendation remains pending amid a D.C. Circuit challenge to the partial order and ongoing compliance with international treaty obligations. These procedural milestones and the administration's directive for expeditious action shape trader views on timelines for any further DEA rulemaking.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania